Open an account

Acura Pharmaceuticals

ACUR · OTC

$0.0001+$0.00 (+0.00%)TodayMarket closed ·
No price history for this range.

About ACUR

Acura Pharmaceuticals, Inc. is a drug delivery company, which engages in the research, development, and commercialization of technologies and products intended to address safe use of medications. The company is headquartered in Palatine, Illinois. The company went IPO on 2000-09-12. Its platform technologies include LIMITX Technology, AVERSION Technology, and IMPEDE Technology. Its LIMITX Technology is designed to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The LIMITX Technology is in development with hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidates. Its AVERSION Technology is to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Its IMPEDE Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.

Employees
0
Headquarters
Palatine, Illinois
Listed
Sep 12, 2000
Sector
Health Care
Industry
Pharmaceuticals
Website
acurapharm.com

ACUR key statistics

Market cap
6.60K
Price-earnings ratio
0.00
Dividend yield
—
Average volume
5.53K
Volume
1.11K
Open price
$0.0001
High today
$0.0001
Low today
$0.0001
52 Week high
$0.01
52 Week low
$0.00

Acura Pharmaceuticals (ACUR) at a glance

Acura Pharmaceuticals (ACUR) last traded at $0.0001, with a market cap of 6.60K and a price-to-earnings ratio of 0.00.

Volume so far is 1.11K shares, below the average of 5.53K shares a day.

Over the past year Acura Pharmaceuticals has ranged from $0.00 to $0.01, and now sits 1% of the way up that range.

Acura Pharmaceuticals met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q1 FY17 it reported $0.03 per share against an estimate of -$0.1122.

ACUR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 76.0% on average.

  1. Q2 FY15: reported -$0.25 per share against an estimate of -$0.102
  2. Q3 FY15: reported -$0.23 per share against an estimate of $0.00
  3. Q4 FY15: reported -$0.08 per share against an estimate of -$0.0306
  4. Q1 FY16: reported -$0.28 per share against an estimate of -$0.2652
  5. Q2 FY16: reported -$0.28 per share against an estimate of -$0.2805
  6. Q3 FY16: reported -$0.19 per share against an estimate of -$0.2703
  7. Q4 FY16: reported $0.13 per share against an estimate of -$0.2754
  8. Q1 FY17: reported $0.03 per share against an estimate of -$0.1122

Similar companies

Companies in the same industry as Acura Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.